Reminder: Invitation to Roche’s virtual EHA 2023 event: Crovalimab in Hematology and Nephrology Montag, 05. Juni 2023 - 10:19

We are pleased to invite investors and analysts to participate in our virtual event on Monday,
12 June 2023, highlighting crovalimab data presented during the congress scientific program on June 9, 2023, and our hematology and nephrology portfolio.

16:30 – 17:30 CEST / 15:30 - 16:30 BST

10:30 – 11:30 am EDT / 7:30 – 8:30 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CEST on the day of the event. > click here

Agenda

Welcome
Bruno Eschli, Head of Investor Relations

Roche hematology franchise and crovalimab deep-dive
Peter Ahnesorg, Franchise Head Hematology, Global Product Strategy

Key crovalimab data presented at EHA 2023
Prof. Alexander Röth, MD, West German Cancer Center, University Hospital Essen

Roche nephrology franchise strategy and pipeline
Jay Garg, MD, Global Development Head of Nephrology and Rheumatology

Q&A

Access to virtual event (pre-registration required)

Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

*privacy notice

Best regards,

Bruno Eschli
Head of Investor Relations

Lilith Esser
Investor Relations Manager

Jan-Philipp Schwarzhans
Investor Relations Officer

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: gerard.tobin@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com